All Online

1 - 11 of 11 results

Refine

Active filters

Coronavirus Disease (COVID-19)
Tile overview image
1 CME CREDIT

Coronavirus New Strain Wide Dark Background
1 CME CREDIT

COVID-19 Panel Discussion: December 2021

1.00 CME/MOC
1.00 AANP | 0.50 Pharmacology

This pandemic required communication among specialists and primary care. In this COVID-19 panel, faculty will team up to discuss the most pressing and frequently asked questions about this disease and its complications.


Bunch of red pills
0.5 CME CREDIT

With ever-changing information on the 2019 novel coronavirus (COVID-19), it is hard to keep the facts straight! There’s new information about vaccines daily but it can be challenging to keep up. In additions there is new data on emerging treatment options. Join Drs. Charles Vega and Ty Gluckman as they team up live to discuss the most recent vaccine efficacy data, the recommendations for boosters, and the new efficacy and safety data for molnupiravir.


Coronavirus New Strain Wide Dark Background
1 CME CREDIT

COVID-19 Update: Panel Discussion (January 2022)

1.00 CME/MOC
1.00 AANP | 0.33 Pharmacology


image of children getting vaccinated with a mask on
0.5 CME CREDIT

With ever-changing information on the 2019 novel coronavirus (COVID-19), it is hard to keep the facts straight! There’s new information about vaccines daily but it can be challenging to keep up. Join Drs. Charles Vega and Ty Gluckman as they team up live to discuss vaccines for children 5-11 years old, and vaccine-associated Myocarditis.


Tile overview image
0.5 CME CREDIT

Are You Up to Date on COVID-19 Diagnosis and Treatment Guidelines? Test Your Mastery!

An Interactive Learning ExperienceThis course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com

0.50 CME/MOC
0.50 AANP | 0.33 Pharmacology

Clinicians must be up to date on the latest guidelines for COVID-19. The proposed self-assessment initiative utilizes an adaptive learning platform to correct confidently held misinformation, covering the latest COVID-19 testing recommendations, Emergency Use Authorizations for treatment of mild to moderate COVID-19, predominant variants, and patient prioritization strategies.


Tile overview image
1 CME CREDIT

COVID-19 Panel Discussion

1.00 CME/MOC
1.00 AANP | 0.50 Pharmacology

This pandemic requires communication among specialists and primary care clinicians. In this COVID-19 panel, expert faculty will team up to discuss the most pressing and frequently asked questions about the disease and its complications.


Frankly Speaking CME 265
0.25 CME CREDIT

Fluvoxamine as a Treatment for COVID-19 - Frankly Speaking EP 265

Guest: Alan M. Ehrlich, MD, FAAFPMusic Credit: Richard Onorato

0.25 CME

Most cases of COVID-19 will resolve without interventions, but some patients are at high risk for complications. Several treatment options for high-risk patients are now available to help prevent the need for hospitalization. Join us to review a recent large, randomized trial evaluating fluvoxamine as a treatment for high-risk patients who were diagnosed with COVID-19.


Frankly Speaking CME 264
0.25 CME CREDIT

COVID-19 and Children - Frankly Speaking EP 264

Guest: Jillian Joseph, MSPAS, PA-CMusic Credit: Richard Onorato

0.25 CME

Get answers to your questions on COVID-19 infection in children. Listen to this podcast to review outcomes and potential risk factors associated with acute COVID-19 infection in this population. Finally, learn the status of immunizations for children younger than 5 years of age.


Frankly Speaking CME 263
0.25 CME CREDIT

Oral Anti-COVID 19 Medications – a Game Changer? - Frankly Speaking EP 263

Guest: Robert A. Baldor, MD, FAAFPMusic Credit: Richard Onorato

0.25 CME

The FDA’s recent emergency use authorization (EUA) for oral agents to treat COVID-19 means that primary care providers (PCPs) will be on the frontline of treating patients with COVID-19. Therefore, PCPs must understand who is eligible for such treatments and how to prescribe them. We will discuss the results of the recent FDA EUA for Pfizer’s Paxlovid and Merck’s molnupiravir antiviral agents and give you the information you need to confidently prescribe them.


Tile overview image
1 CME CREDIT

Emerging Infectious Diseases: What Primary Care Needs to Know

1.00 CME/MOC
1.00 AANP | 0.33 Pharmacology

Since March 2020 we have been in the middle of a pandemic related to SARS-CoV2, an infection derived from the movement of a non-human coronavirus into humans. Emerging (and re-emerging) infections occur due to many factors, including population growth, travel, movement out of rural areas and more. Learn about what emerging infections to be on the lookout for during this 60 minute session.